Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters

Psychopharmacology

Volumn 119, Issue 2, 1995, Pages 231-238

  Wetzel, H ^a   Szegedi, A ^a   Hain, Ch ^a   Wiesner, J ^a   Schlegel, S ^a   Benkert, O ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

"Atypical" neuroleptics; ICI 204 636; Pharmaco EEG; Prolactin; Schizophrenia; Seroquel

Indexed keywords

NEUROLEPTIC AGENT; PROLACTIN; QUETIAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MALE; NEUROENDOCRINOLOGY; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; ELECTROENCEPHALOGRAPHY; FEMALE; HUMAN; MALE; MIDDLE AGE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THYROTROPIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0029076858     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/BF02246165     Document Type: Article

References (33)

1. Side effects of clozapine and their management
2. Clozapine-induced agranulocytosis: a situation report up to August 1976
3. Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist
4. Clozapine. A novel antipsychotic agent
5. Effects of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy
6. Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5HT2 receptor blocking agent
7. Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates
8. Prevalence and severity of akathisia in patients on clozapine
9. Serotonergic involvement with neuroleptic catalepsy
10. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve
11. EEG an human psychopharmacology
12. C-EEG brain mapping in DSM -III schizophrenics after acute and chronic haloperidol treatment
13. New antipsychotics: classification, efficacy and adverse effects
14. Seroquel: electrophysiological profile of a potential atypical antipsychotic
15. Clozapine and seizures
16. An absolute must in clinico-pharmacological research: pharmaco-electro-encephalography, its possibilities and limitations
17. Qualitative and quantitative EEG findings in schizophrenia
18. Clozapine for the treatment-resistant schizophrenic
19. Paroxysmal EEG activity and psychopathology during the treatment with clozapine
20. Leponex-associated granulocytopenia: a review of the situation
21. Clozapine: guidelines for clinical management
22. The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years
23. Vigilance and the EEG: psychological, physiological and pharmacological aspects
24. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values
25. Seroquel: behavioral effects in conventional and novel tests for atypical antipsycotic drug
26. Tolerability and therapeutic effect of clozapine
27. Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker
28. Seroquel: biochemical profile of a potential atypical antipsychotic
29. EEG abnormalities associated with clozapine treatment
30. Multiple dopamine D4 receptor variants in the human population
31. Savoxepine: invalidation of an “atypical” neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patients